Contraception
Volume 64, Issue 6 , Pages 339-343, December 2001

Mifepristone abortion in minors

  • Rachael H. Phelps

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1-716-341-6292; fax: +1-716-341-6293
    • Department of Family Medicine, Reproductive Health Program, University of Rochester, Rochester, NY, USA
  • ,
  • Eric A. Schaff

      Affiliations

    • Department of Family Medicine, Reproductive Health Program, University of Rochester, Rochester, NY, USA
  • ,
  • Stephen L. Fielding

      Affiliations

    • Department of Family Medicine, Reproductive Health Program, University of Rochester, Rochester, NY, USA

Abstract 

Approximately one-third of pregnant teenagers in the U.S. choose abortion. This prospective study evaluated whether medical abortion with mifepristone and misoprostol is physically and emotionally acceptable in adolescents. Adolescents 14- to 17-years-old, with pregnancies ≤56 days gestation, and seeking abortion services with parental consent from at least one parent were enrolled. Mifepristone (200 mg) was administered, followed 2 days later by 800 μg of misoprostol administered vaginally. Follow-up visit occurred on Day 4–8 to confirm abortion completion. Questionnaires regarding acceptability of the procedure as well as emotional coping were administered at the initial visit, at the follow-up visit, and by phone at 4 weeks postabortion.

All 28 adolescents had complete medical abortions without complications or surgical intervention, and five minors did not require misoprostol. At the Day 4–8 follow-up visit, 75% of teens found the procedure acceptable, and that increased to 96% by the 4-week visit. Although 57% reported stress and 43% reported fear initially, by 4 weeks postabortion only 21% of the teens reported stress, and 8% were still experiencing fear. In addition, the minors’ satisfaction with their abortion decision increased from 43% to 79% by 4 weeks postabortion. Medical abortion with mifepristone and misoprostol was highly effective and well tolerated, physically and emotionally, by adolescents in our sample. A larger clinical trial is needed to generalize these findings to other adolescent populations seeking medical abortion services.

Keywords:  Mifepristone, Misoprostol, Abortion, Adolescents, Teenagers, Minors

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0010-7824(01)00296-7

Contraception
Volume 64, Issue 6 , Pages 339-343, December 2001